Search results
Added:
3 years ago
The most common cause of heart failure with reduced ejection fraction (HFrEF) in the industrialised world is coronary heart disease.1 Patients with an ischaemic aetiology of left ventricular systolic dysfunction have significantly higher mortality rates than those with non-ischaemic aetiologies.2 This more aggressive course represents the convergence of ischaemic myocardial fibrosis and…
View more
Added:
6 years ago
In this short video, Dr Keith G Oldroyd discusses which trials best support the use of multivessel disease percutaneous coronary intervention (MVD PCI).
View more
Added:
1 year ago
In this short and engaging episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) share their take on the most impactful hot-line and late-breaking trials from ESC 2022.
Which trials should we look out for?
Trials covered in detail include:
TAILOR-PCI: Tailored Antiplatelet Therapy Following PCI
ASCEND: A Study of…
View more
Added:
8 months ago
What is hot at ESC 2023?
In this episode of View of the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, NL) preview the hot line and late-breaking data presented at ESC Congress 2023.
With their dynamic analysis, they place these highly anticipated trials within a context, highlighting the real-world implications tied to the data releases.
Top trials…
View more
Added:
2 weeks ago
ACC 2024 — Late-breaker host, Dr Harriette Van Spall and Principal Investigator, Dr C Michael Gibson discuss the AEGIS-II trial (CSL Behring) (NCT03473223).This phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study investigated the efficacy and safety of an apolipoprotein A-I (apoA-I), CSL112 in patients with acute coronary syndrome (ACS). Investigators enrolled…
View more
Added:
4 months ago
In this week's Parallax, Dr Ankur Kalra welcomes back Dr Sukhjinder Nijjer for their much-anticipated annual review of advancements in cardiovascular medicine that defined the year 2023.Dr Nijjer, a Consultant Cardiologist in the UK, serves as the President of the Royal Society of Medicine and is an Honorary Senior Clinical Lecturer at Imperial College London.Drs Kalra and Nijjer share their…
View more
Added:
1 year ago
What are the take-home messages from ESC 22 and what are the implications for practice?
In this short wrap-up video of ESC 22, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) review the most impactful hot line and late-breaking trials of ESC Congress 2022.
Trials covered in detail include:
On clinical judgement after PCI
00:35:27:REVIVED-BCIS2: Study of…
View more
Added:
5 months ago
AHA 23 - Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, US), interventional cardiologist and Past President of the American College of Cardiology (ACC) highlights the top three late-breaking science trials from the 2023 AHA Scientific Sessions with the potential to change medical practices.Trials discussed in detail include:SELECT: Semaglutide and Cardiovascular Outcomes in Obesity…
View more
ACC 2022: Late-breaking Science Video Collection
Video Series
Added:
1 year ago
